1361391-19-6

Upstream product

• 556-48-9 1,4-Cyclohexanediol 
• 111196-81-7 2-chloro-5-ethylpyrimidine 
• 1361391-16-3 4-(5-ethylpyrimidin-2-yloxy)cyclohexanone 

Downstream Products

• 1361391-82-3 2-(4-(4-bromo-2,6-difluorophenoxy)cyclohexyloxy)-5-ethylpyrimidine 
• 1361391-91-4 6-(4-(5-ethylpyrimidin-2-yloxy)cyclohexyloxy)-N-(4-(methylsulfonyl)phenyl)pyridazin-3-amine 
• 1361392-06-4 2-(4-(3,5-difluoro-4'-(methylsulfonyl)biphenyl-4-yloxy)cyclo hexyloxy)-5-ethylpyrimidine 
• 1361392-01-9 5-ethyl-2-(4-(4-(4-(methylsulfonyl)phenoxy)butoxy)cyclohexyloxy)pyrimidine 

Relevant academic research and scientific papers

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.